



### New Programs

Effective 01 August 2023, the BC Cancer Provincial Systemic Therapy Program has approved the following new treatment programs. The full details of these programs can be found on the BC Cancer website in the [Chemotherapy Protocols](#) section.

#### Breast

**Trastuzumab Deruxtecan (ENHERTU) for Metastatic HER-2 Positive Breast Cancer (BRAVENH)** – The BC Cancer Breast Tumour Group is introducing trastuzumab deruxtecan (ENHERTU) for treatment of HER2-positive unresectable or metastatic breast cancer after prior anti-HER2 therapy. Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate consisting of trastuzumab linked to the topoisomerase I inhibitor deruxtecan.

In the phase III DESTINY-Breast03 trial compared to trastuzumab emtansine (KADCYLA), trastuzumab deruxtecan (ENHERTU) was associated with improved progression-free survival (DFS) (12-month 75.8% vs. 34.1%, hazard ratio [HR] 0.37).[1] The toxicities of trastuzumab deruxtecan (ENHERTU) include neutropenia/febrile neutropenia, decreased left ventricular ejection fraction and interstitial lung disease and pneumonitis. See Cancer Drug Manual monograph for more details on toxicities. Note that there is a risk of medication errors between trastuzumab deruxtecan (ENHERTU), trastuzumab (HERCEPTIN and funded biosimilar products), and trastuzumab emtansine (KADCYLA).

#### Gynecological

**Neoadjuvant or Adjuvant Treatment of Endometrial Cancer (GOENDAJCAT) and Treatment of Advanced or Recurrent Endometrial Cancer (GOENDAVCAT) using CARBOplatin and PAclitaxel** – The BC Cancer Gynecological Tumour Group is introducing two protocols using carboplatin and paclitaxel for the treatment of endometrial cancer (EC) to replace the current GOENDCAT protocol. All new patients should be started on either GOENDAJCAT or GOENDAVCAT, while the current GOENDCAT protocol would continue to be posted until all existing patients have completed their treatment.

These new protocols would reflect the change in the management of EC with the incorporation of molecular classification, which has been updated in the [BC Cancer Management Manual](#). [2] Molecular subtyping of patients receiving adjuvant chemoradiotherapy vs. radiotherapy alone demonstrated the strong prognostic value of each molecular subtype, with significant differences in 5-year recurrence-free survival [2]:

	Chemoradiotherapy	Radiotherapy
p53 abnormal	59%	36%
POLE mutant	100%	97%
Mismatch Repair Deficient	68%	76%
No specific molecular profile	80%	68%

## Editor's Choice

### New Programs

#### Myeloma

**Lenalidomide, Bortezomib and Dexamethasone as Induction Pre-Stem Cell Transplant for Multiple Myeloma (MYBLDPRE)** – The BC Cancer Myeloma Tumour Group is introducing lenalidomide, bortezomib and dexamethasone (RVd) as induction pre-stem cell transplant for patients with previously untreated multiple myeloma. This induction regimen is recommended by CADTH based on findings that response, relapse, PFS and overall survival broadly favoured RVd over bortezomib-cyclophosphamide-dexamethasone.[4] The RVd regimen is associated with manageable toxicities consistent with known safety profiles for each drug.

#### References

1. Cortés J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. *N Engl J Med*. 2022;386(12):1143-54.
2. León-Castillo A, de Boer SM, Powell ME, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. *J Clin Oncol*. 2020;38(29):3388-3397.
3. BC Cancer Management Manual. Endometrium. Available at: <http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-management-manual/gynecology/endometrium>.
4. CADTH Reimbursement Review. Provisional Funding Algorithm. Multiple Myeloma. May 2022.

## Highlights of Revised Protocols

### DPYD Tests Added to Fluorouracil and Capecitabine Protocols

All protocols containing fluorouracil and/or capecitabine have been revised to include baseline *DPYD* genotyping test and hyperlink to dosing recommendations based on *DPYD* Activity Score. Patients with genetic variation in the *DPYD* gene can be at risk of severe toxicities with fluorouracil and/or capecitabine due to reduced metabolism of the active metabolites. Therefore, patients with an identified *DPYD* gene variant should start with reduced dose based on their predicted DPD activity. See the [May](#) issue of Systemic Therapy Update for more background information.

## Drug Update

### Crisantaspase Recombinant (RYLAZE) – New Asparaginase Product

Crisantaspase Recombinant (RYLAZE) is a new asparaginase product containing recombinant asparaginase identical to asparaginase *Erwinia chrysanthemi*. It has been added to the Benefit List for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in patients with hypersensitivity to asparaginase *Escherichia coli* (e.g., pegaspargase [ONCASPARG]). In addition, it will also be funded for pediatric patients with low-risk acute myeloid leukemia who require short-acting asparaginase during Intensification III protocol.

Crisantaspase (RYLAZE) meets an important need in the Canadian practice setting due to scarcity of other options in these patients after the discontinuation of asparaginase *Erwinia chrysanthemi* (ERWINASE).

## Drug Update

### Crisantaspase Recombinant (RYLAZE) – New Asparaginase Product

<b>Asparaginase from <i>E.coli</i></b>	
Asparaginase (KIDROLASE)	Asparaginase from <i>E.coli</i> (withdrawn from Canadian market)
Pegaspargase (ONCASPAR)	Asparaginase from <i>E.coli</i> attached to polyethylene glycol
Calaspargase pegol (ASPARLAS)	Asparaginase from <i>E. coli</i> attached to monomethoxy- polyethylene glycol (US only)
<b>Asparaginase from <i>Erwinia chrysanthemi</i></b>	
Asparaginase-erwinia (ERWINASE)	Asparaginase from <i>Erwinia chrysanthemi</i> (withdrawn from Canadian market).
Crisantaspase recombinant (RYLAZE)	Recombinant asparaginase identical to asparaginase from <i>Erwinia chrysanthemi</i>

## Provincial Systemic Therapy Policies

### III-20 Prevention and Management of Extravasation of Chemotherapy

The policy has been updated to clarify that paclitaxel and oxaliplatin are classified as irritants for the purpose of precautionary measures, but are treated to have vesicant-potential in the event of extravasation.

All documents are available in the [Cancer Drug Manual<sup>©</sup>](#) on the BC Cancer website.

### New Documents

The **Trastuzumab deruxtecan Interim Monograph** has been expanded into a full **Monograph** and a **Patient Handout** has been developed. Expert review was provided by Dr. Nathalie Levasseur (medical oncologist, BC Cancer Breast Tumour Group) and Megan Darbyshire (tumour group pharmacist, BC Cancer Provincial Pharmacy). All monograph sections have been reviewed and updated. The following sections have been added or expanded: *Pharmacokinetics, Special Precautions, Side Effects, Interactions, and Dosage Guidelines*. Trastuzumab deruxtecan is a HER2-directed antibody drug conjugate used in the treatment of breast cancer. Usual dosing is 5.4 mg/kg IV given on days 1 of a 21 day cycle.

Highlights from these documents include:

- trastuzumab deruxtecan (ENHERTU<sup>®</sup>) is NOT interchangeable with trastuzumab (HERCEPTIN<sup>®</sup>) or trastuzumab emtansine (KADCYLA<sup>®</sup>)
- cases of fatal interstitial lung disease (ILD) and pneumonitis have been reported
- monitor LVEF as clinically indicated

**Crisantaspase recombinant** (asparaginase *Erwinia crysanthemii*) has been added to the **Chemotherapy Preparation and Stability Chart**.

### Revised Documents

#### Cetuximab Monograph

*Uses:* added squamous cell carcinoma

*Cautions:* updated Pregnancy and Breastfeeding

*Parenteral Administration:* added new BC Cancer protocol SMAVCET

*Dosage Guidelines:* added new BC Cancer protocol SMAVCET

#### Niraparib Monograph

*Supply and Storage:* added tablet formulation

#### Niraparib Patient Handout

*First bullet:* updated to include tablet formulation

*Storage bullet:* updated to include tablet formulation

*Side effects (diarrhea):* added tablet formulation information and updated section to warning about dehydration

*Throughout:* updated to current template wording

#### Regorafenib Monograph

*Uses:* added osteosarcoma

*Cautions:* added pediatric patients to *Special Populations*; updated *Fertility* and *Pregnancy* sections

*Side effects:* added epistaxis to table; updated paragraph on hemorrhage

# Benefit Drug List

## New Programs

Effective 01 August 2023, the following new treatment programs have been added to the BC Cancer Benefit Drug List:

Protocol Title	Protocol Code	Benefit Status
Palliative Therapy for Metastatic Breast Cancer using <b>Trastuzumab Deruxtecan (ENHERTU)</b>	<b>BRAVENH</b>	Class I
Neoadjuvant or Adjuvant Treatment of Endometrial Cancer using <b>CARBOplatin</b> and <b>PACLitaxel</b>	<b>GOENDAJCAT</b>	Class I
Treatment of Advanced or Recurrent Endometrial Cancer using <b>CARBOplatin</b> and <b>PACLitaxel</b>	<b>GOENDAVCAT</b>	Class I
Treatment of Multiple Myeloma using <b>Lenalidomide, Bortezomib</b> and <b>Dexamethasone</b> as Induction Pre-Stem Cell Transplant	<b>MYBLDPRE</b>	Class I
Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in Adult Patients Allergic to Asparaginase (KIDROLASE) or Pegaspargase (ONCASPAR) using <b>Crisantaspase Recombinant (RYLAZE)</b>	<b>LKNOS, LYNOS</b>	Class I
Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in Pediatric Patients Allergic to Asparaginase (KIDROLASE) or Pegaspargase (ONCASPAR) using <b>Crisantaspase Recombinant (RYLAZE)</b>	<b>Pediatric</b>	Class I
Treatment of Children with Low-Risk Acute Myeloid Leukemia Who Require Short-Acting Asparaginase per COG AAML 1831 Study using <b>Crisantaspase Recombinant (RYLAZE)</b>	<b>Pediatric</b>	Class I
Treatment of Children with T-cell Lymphoblastic Lymphoma with <b>Bortezomib</b>	<b>Pediatric</b>	Class I

## List of Revised Protocols, Pre-Printed Orders and Patient Handouts

**BC Cancer Protocol Summaries, Provincial Pre-Printed orders (PPPOs) and Patient Handouts** are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

### NEW Protocols, PPPOs and Patient Handouts (*new documents checked* )

Code	Protocol Title	Protocol	PPPO	Handout
<b>BRAVENH</b>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Deruxtecan (ENHERTU)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--
<b>GOENDAJCAT</b>	Neoadjuvant or Adjuvant Treatment of Endometrial Cancer using CARBOplatin and PACLitaxel	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
<b>GOENDAVCAT</b>	Treatment of Advanced or Recurrent Endometrial Cancer using CARBOplatin and PACLitaxel	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
<b>MYBLDPRE</b>	Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and Dexamethasone as Induction Pre-Stem Cell Transplant	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

### REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
<b>BR   Breast</b>				
<b>BRAVKAD</b>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)	<i>exclusions updated</i>	--	--
<b>CN   Neuro-Oncology</b>				
<b>CNETO</b>	Palliative Treatment of Patients with Recurrent Malignant Gliomas and Ependymoma Using Low Dose Etoposide	<i>minor typo corrected</i>	--	--
<b>GI   Gastrointestinal</b>				
<b>GILEN</b>	Therapy of Advanced Hepatocellular Carcinoma using Lenvatinib	--	<i>treatment clarified</i>	--
<b>GO   Gynecological</b>				

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
GOENDCAT	Treatment of Primary Advanced or Recurrent Endometrial Cancer using CARBOplatin and PACLitaxel	<i>note added to direct new patients</i>	--	--
<b>LU   Lung</b>				
LUAJPP	Adjuvant CISplatin and Pemetrexed Following Resection of Non-Small Cell Lung Cancer	--	<i>prechemo metrics updated</i>	--
LUAVATZ	Treatment of Advanced Non-Small Cell Lung Cancer Using Atezolizumab	<i>Eligibility and exclusions updated</i>	--	--
LUAVATZ4	Treatment of Advanced Non-Small Cell Lung Cancer Using 4-Weekly Atezolizumab	<i>Eligibility and exclusions updated</i>	--	--
LUAVNIV	Treatment of Advanced Non-Small Cell Lung Cancer Using Nivolumab	<i>Eligibility and exclusions updated</i>	--	--
LUAVNIV4	Treatment of Advanced Non-Small Cell Lung Cancer Using 4-Weekly Nivolumab	<i>Eligibility and exclusions updated</i>	--	--
LUAVPCIPNI	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with PACLitaxel, CARBOplatin, Ipilimumab and Nivolumab	<i>Eligibility and exclusions updated</i>	--	--
LUAVPCPMB	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with PACLitaxel, CARBOplatin and Pembrolizumab	<i>Eligibility and exclusions updated</i>	--	--
LUAVPEM	Second-Line Chemotherapy of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed	--	<i>prechemo metrics updated</i>	--
LUAVPGPMB	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Platinum, Gemcitabine and Pembrolizumab	<i>Eligibility and exclusions updated</i>	--	--
LUAVPMB	Treatment of Advanced Non-Small Cell Lung Cancer Using Pembrolizumab	<i>Eligibility and exclusions updated</i>	--	--
LUAVPMB6	Treatment of Advanced Non-Small Cell Lung Cancer Using 6-Weekly Pembrolizumab	<i>Eligibility and exclusions updated</i>	--	--
LUAVPMBF	First-Line Treatment of Advanced Non-Small Cell Lung Cancer Using Pembrolizumab	<i>Eligibility and exclusions updated</i>	--	--
LUAVPMBF6	First-Line Treatment of Advanced Non-Small Cell Lung Cancer Using 6-Weekly Pembrolizumab	<i>Eligibility and exclusions updated</i>	--	--
LUAVPMTN	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed	--	<i>prechemo metrics updated</i>	--

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
LUAVPP	First-Line Treatment of Advanced Non-Small Cell Lung Cancer with Platinum and Pemetrexed	--	<i>prechemo metrics updated</i>	--
LUAVPIPNI	First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab	<i>Eligibility and exclusions updated</i>	<i>prechemo metrics updated</i>	--
LUAVPPMBM	Maintenance Therapy of Advanced Non-Squamous Non-Small Cell Lung Cancer with Pemetrexed and Pembrolizumab	--	<i>prechemo metrics updated</i>	--
LUAVPPMB	First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed and Pembrolizumab	<i>Eligibility and exclusions updated</i>	<i>prechemo metrics updated</i>	--
LUMMPP	Treatment of Malignant Mesothelioma with Platinum and Pemetrexed	--	<i>prechemo metrics updated</i>	--
<b>LY   Lymphoma</b>				
MYLENMTN	Maintenance Therapy of Multiple Myeloma Using Lenalidomide	<i>CAP deleted for subsequent MYLDREL</i>	--	--

**Fluorouracil and capecitabine protocols have been revised to include baseline *DPYD* testing and hyperlink to dosing recommendations based on *DPYD* Activity Score:**

Code	Protocol Title
BRAJCAP	Therapy of Adjuvant Breast Cancer using Capecitabine
BRAJCMFPO	Adjuvant Therapy for High-Risk Breast Cancer Using Cyclophosphamide (oral), Methotrexate and Fluorouracil
BRAJFEC	Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide
BRAJFECD	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin, Cyclophosphamide and DOCETaxel
BRAJFCDT	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide Followed by DOCETaxel and Trastuzumab
BRAVCAP	Therapy for Metastatic Breast Cancer Using Capecitabine
BRAVCMF	Palliative Therapy for Advanced Breast Cancer Using Cyclophosphamide, Methotrexate and Fluorouracil
BRAVLCAP	Therapy for Metastatic Breast Cancer Using Capecitabine and Lapatinib
BRAVTCAP	Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab and Capecitabine
UBRAVTTCAP	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab, Tucatinib, and Capecitabine
GIAJCAP	Adjuvant Therapy of Colon Cancer Using Capecitabine
GIAJCAPOX	Palliative Therapy of Advanced Colorectal Cancer using Capecitabine
GIAJFFOX	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer Using Oxaliplatin, Fluorouracil and Leucovorin

<b>Code</b>	<b>Protocol Title</b>
<b>GIAJFL</b>	Adjuvant Therapy of Colon Cancer Using Fluorouracil Injection and Infusion and Leucovorin Infusion
<b>GIAVCAP</b>	Palliative Therapy of Advanced Colorectal Cancer using Capecitabine
<b>GIAVCAPB</b>	Palliative Therapy of Advanced Colorectal Cancer using Capecitabine and Bevacizumab
<b>GIAVFL</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Fluorouracil Injection and Infusion and Leucovorin Infusion
<b>GIAVTZCAP</b>	Palliative Therapy of Metastatic Neuroendocrine Cancer Using Temozolomide and Capecitabine
<b>GIBAJCAP</b>	Adjuvant Therapy of Biliary Cancer using Capecitabine
<b>GICAPIRI</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan and Capecitabine in Patients Unsuited for GIFOLFIRI
<b>GICAPOX</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin and Capecitabine
<b>GICART</b>	Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy
<b>GICIRB</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Bevacizumab and Capecitabine
<b>GICOXB</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Bevacizumab and Capecitabine
<b>GICPART</b>	Combined Modality Therapy for Carcinoma of the Anal Canal Using CISplatin, Capecitabine and Radiation Therapy
<b>GIEFFOXRT</b>	Combined Modality Therapy for Locally Advanced Esophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin, and Radiation Therapy
<b>GIENDO2</b>	Palliative Therapy for Pancreatic Endocrine Tumours using Streptozocin and DOXOrubicin
<b>GIFFIRB</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil, Leucovorin and Bevacizumab
<b>GIFFIRPAN</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil, Leucovorin, and PANitumumab
<b>GIFFOXB</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil, Leucovorin and Bevacizumab
<b>GIFFOXPAN</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil, Leucovorin, and PANitumumab
<b>GIFIRINOX</b>	Palliative Combination Chemotherapy for Advanced Pancreatic Adenocarcinoma Using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin
<b>GIFOLFIRI</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil and Leucovorin
<b>GIFOLFOX</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil and Leucovorin
<b>GIFUART</b>	Combined Modality Curative Therapy for Carcinoma of the Anal Canal Using Mitomycin, Fluorouracil and Radiation Therapy
<b>GIFUC</b>	Palliative Chemotherapy for Upper Gastrointestinal Tract Cancer (Gastric, Esophageal, Gall Bladder Carcinoma and Cholangiocarcinoma) and Metastatic Anal Cancer Using Infusional Fluorouracil and CISplatin
<b>GIFUPART</b>	Combined Modality Curative Therapy for Carcinoma of the Anal Canal Using CISplatin, Infusional Fluorouracil and Radiation Therapy
<b>GIGAJCOX</b>	Adjuvant Chemotherapy in Gastric Cancer Patients with D2 Resection (Node Negative) or Ineligible for Adjuvant Chemoradiation Using Oxaliplatin and Capecitabine
<b>GIGAJCPRT</b>	Adjuvant Chemotherapy of Gastric Cancer Patients with Completely Resected Gastric Cancer Using CISplatin and Capecitabine and Radiation Therapy

<b>Code</b>	<b>Protocol Title</b>
<b>GIGAJFFOX</b>	Adjuvant Chemotherapy of Gastric Cancer Patients with D2 Resection (Node Negative) or Ineligible for Adjuvant Chemoradiation Using Oxaliplatin, Fluorouracil, and Leucovorin
<b>GIGAVCC</b>	Palliative Therapy of Metastatic or Locally Advanced Anal Squamous Cell Carcinoma using CISplatin and Capecitabine
<b>GIGAVCCT</b>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Using CISplatin, Capecitabine and Trastuzumab
<b>GIGAVCFT</b>	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using CISplatin, Infusional Fluorouracil and Trastuzumab
<b>GIGAVCOX</b>	Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Capecitabine and Oxaliplatin
<b>GIGAVCOXN</b>	First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Capecitabine and Nivolumab
<b>GIGAVCOXP</b>	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Capecitabine and Pembrolizumab
<b>GIGAVCOXT</b>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Using Capecitabine, Oxaliplatin, and Trastuzumab
<b>GIGAVFFOX</b>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin
<b>GIGAVFFOXN</b>	First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab
<b>GIGAVFFOXP</b>	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab
<b>GIGAVFFOXT</b>	Palliative Treatment of Metastatic or Locally Advanced HER-2 Positive Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Using Oxaliplatin, Fluorouracil, Leucovorin, and Trastuzumab
<b>GIGECC</b>	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus Using Epirubicin, CISplatin and Capecitabine
<b>GIGFLODOC</b>	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus using DOCEtaxel, Oxaliplatin, Infusional Fluorouracil, and Leucovorin
<b>GIGFOLFIRI</b>	Second Line Palliative Combination Chemotherapy for Metastatic Gastric or Esophageal Adenocarcinoma Using Irinotecan, Fluorouracil and Leucovorin
<b>GIPAJFIROX</b>	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma Using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin
<b>GIPAJGCAP</b>	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma Using Capecitabine and Gemcitabine
<b>GIPAVCAP</b>	Second line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma Using Capecitabine
<b>GIPAVFFIRI</b>	Second Line Treatment for Metastatic Pancreatic Cancer Using Irinotecan, Fluorouracil and Leucovorin
<b>GIPAVFFOX</b>	Palliative Combination Chemotherapy for Metastatic Pancreatic Cancer Using Oxaliplatin, Fluorouracil, and Leucovorin
<b>GIRAJCOX</b>	Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin and Capecitabine
<b>GIRAJFFOX</b>	Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin, Fluorouracil and Leucovorin
<b>GIRCAP</b>	Adjuvant Therapy for Stage II and III Rectal Cancer Previously Treated with Preoperative Radiation Therapy using Capecitabine
<b>GIRCRT</b>	Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma Using Capecitabine and Radiation Therapy
<b>GIRINFRT</b>	Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma Using Capecitabine, Infusional Fluorouracil and Radiation Therapy

<b>Code</b>	<b>Protocol Title</b>
<b>GUFUPRT</b>	Combined Modality Therapy for Squamous Cell Cancer of the Genitourinary System Using Fluorouracil and CISplatin with Radiation
<b>HNAVCAP</b>	Treatment Of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck With Capecitabine
<b>HNAVFUFA</b>	Fluorouracil and Leucovorin for Recurrent Head and Neck Cancer (Squamous Cell Carcinoma)
<b>HNAVFUP</b>	Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum
<b>HNAVFPMB</b>	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Using Platinum, Fluorouracil and Pembrolizumab
<b>HNLACFRT</b>	Combined Chemotherapy (CARBOplatin and Fluorouracil) and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
<b>HNLADCF</b>	Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with DOCEtaxel, CISplatin and Infusional Fluorouracil
<b>HNAVCAP</b>	Treatment Of Recurrent Or Metastatic Nasopharyngeal Cancer With Capecitabine
<b>HNAVFUFA</b>	Treatment of Recurrent or Metastatic Nasopharyngeal Cancer with Fluorouracil and Leucovorin
<b>HNAVFUP</b>	Treatment for Advanced Nasopharyngeal Cancer of the Head and Neck using Platinum and Fluorouracil
<b>HNSAVFAC</b>	Palliative Therapy for Advanced Salivary Gland Cancers Using Cyclophosphamide, DOXOrubicin and Fluorouracil
<b>HNSAVFUP</b>	Treatment of Advanced Head and Neck Cancer Using CISplatin and Fluorouracil

## Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: <a href="http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update">www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update</a>		
Systemic Therapy Update Editor	604-877-6000 x 672649	<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Oncology Drug Information	604-877-6275	<a href="mailto:druginfo@bccancer.bc.ca">druginfo@bccancer.bc.ca</a>
Cancer Drug Manual Editor	250-519-5500 x 693742	<a href="mailto:nbadry@bccancer.bc.ca">nbadry@bccancer.bc.ca</a>
Pharmacy Oncology Certification	250-712-3900 x 686820	<a href="mailto:rxchemocert@bccancer.bc.ca">rxchemocert@bccancer.bc.ca</a>
Nurse Educators	604-877-6000 x 672638	<a href="mailto:nursinged@bccancer.bc.ca">nursinged@bccancer.bc.ca</a>
CAP – Compassionate Access Program	604-877-6277	<a href="mailto:cap_bcca@bccancer.bc.ca">cap_bcca@bccancer.bc.ca</a> fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	<a href="mailto:oscar@bccancer.bc.ca">oscar@bccancer.bc.ca</a> fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 <a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Library Document Delivery	604-675-8002	<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Pharmacy Professional Practice	604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
Professional Practice, Nursing	604-877-6000 x 672623	<a href="mailto:BCCancerPPNAdmin@ehcnet.phsa.ca">BCCancerPPNAdmin@ehcnet.phsa.ca</a>
Provincial Systemic Therapy Program	604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: <a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>		

## Editorial Review Board

Mario de Lemos, PharmD, MSc(Oncol) (Interim Editor)  
 Jeevan Dosanjh, RN, BScN  
 Alina Gerrie, MD, MPH, FRCPC

Samuel Hackett, RN, BScN, CON(C)  
 Alison Pow, BScPharm